A novel plasma proteomic‐based model for predicting liver fibrosis in HIV/HBV co‐infected adults
A novel plasma proteomic‐based model for predicting liver fibrosis in HIV/HBV co‐infected adults
复制标题
DOI：
10.1002/jmv.28222
复制
发表时间：
2022-10
影响因子：
12.7
通讯作者：
Rui Yuan;Yongxi Zhang;Liping Deng;Xingxia Yu;K. Zhuang;Xiaoping Chen;Q. Cao;H. Ping;Hengning Ke;X. Gui;R. Yang
中科院分区：
文献类型：
--
作者：
Rui Yuan;Yongxi Zhang;Liping Deng;Xingxia Yu;K. Zhuang;Xiaoping Chen;Q. Cao;H. Ping;Hengning Ke;X. Gui;R. Yang
建立一个血浆模型来预测HIV/HBV合并感染个体的肝纤维化风险。采用定量液相色谱-串联质谱法（LC-MS/MS）鉴定从HIV/HBV合并感染伴和不伴肝纤维化的个体中采集的血浆中差异表达的蛋白质（DEP）。总共鉴定了97种DEP，其中11种被进一步验证为潜在的生物标志物，免疫球蛋白和补体成分是最常见的蛋白质。发现这些显著改变的蛋白质介导病理生理学途径，包括体液免疫应答、补体和凝血级联反应以及补体激活。已建立了一个视觉逻辑模型，其中包括免疫球蛋白重链可变区3 - 20（IGHV 3 - 20）、免疫球蛋白重链可变区1 - 24（IGHV 1 - 24）和巨噬细胞集落刺激因子1受体（CSF 1 R）蛋白，用于预测HIV/HBV合并感染个体的肝纤维化。初步结论表明，IGHV 3 - 20、IGFHV 1 - 24和CSF 1 R的组合有望成为HIV/HBV合并感染背景下肝纤维化的预测模型，需要进一步验证。
To establish a plasma model to predict the risk of liver fibrosis in HIV/HBV co‐infected individuals. Quantitative liquid chromatography‐tandem mass spectrometry(LC‐MS/MS) was used to identify differentially expressed proteins (DEPs) in plasma collected from HIV/HBV co‐infected individuals with and without liver fibrosis. In total, 97 DEPs were identified, among which 11 were further validated as potential biomarkers, with immunoglobulin and complement components being the most common proteins. These markedly altered proteins were found to mediate pathophysiological pathways, including humoral immune response, complement and coagulation cascades, and complement activation. A visual logistic model, in which immunoglobulin heavy variable 3‐20 (IGHV3‐20), immunoglobulin heavy variable 1‐24 (IGHV1‐24), and macrophage colony‐stimulating factor 1 receptor (CSF1R) proteins were included, has been established to predict liver fibrosis in HIV/HBV co‐infected individuals. The preliminary conclusion showed that the combination of IGHV3‐20, IGFHV1‐24, and CSF1R is expected to become a predictive model for liver fibrosis in the context of HIV/HBV co‐infection and a further validation should be performed.